JNJ 63723283

Drug Profile

JNJ 63723283

Alternative Names: JNJ-63723283

Latest Information Update: 25 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Janssen Research & Development
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Immunomodulators; PDCD 1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Multiple myeloma
  • Phase I/II Solid tumours

Most Recent Events

  • 25 Oct 2017 Phase-II/III clinical trials in Multiple myeloma (Combination therapy, Second-line therapy or greater) in Belgium (IV) (EudraCT2017-002611-34)
  • 01 Nov 2016 Phase-I/II clinical trials in Solid tumours (Late-stage disease) in USA, Spain (IV) (NCT02908906)
  • 19 Sep 2016 Janssen Research and Development plans a phase I/II trial in Solid tumours (Late-stage disease) in USA and Spain (NCT02908906)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top